Harmony Biosciences recently completed its acquisition of Zynerba Pharmaceuticals. I am excited for us to progress their work in pursuit of a treatment option for people living with Fragile X syndrome.
Read morePrader-Willi
FRAXA Research Foundation Joins COMBINEDBrain Consortium for Fragile X Biomarker Research
![FRAXA Research Foundation Joins COMBINEDBrain Consortium for Fragile X Biomarker Research](https://www.fraxa.org/wp-content/uploads/2023/05/Fragile-X-Biomarker-Research-hero-720x300.png)
Help accelerate research on Fragile X syndrome biomarkers by contributing samples to the COMBINEDBrain Consortium’s project. Contact Katie Clapp at FRAXA Research Foundation to learn how you can participate.
Read moreNeurodevelopmental Drug Development Summit Presentation
![Neurodevelopmental Drug Development Summit Presentation](https://www.fraxa.org/wp-content/uploads/2022/01/NDD-Summit-fi-720x300.png)
FRAXA president and co-founder, Katie Clapp was one of three patient advocacy leaders invited to kick off the Neurodevelopmental Drug Development Summit with a presentation on Fragile X, and FRAXA Scientific Advisor, Dr. Elizabeth Berry-Kravis also presented lessons learned from clinical trials in Fragile X Syndrome.
Read moreRole of FMRP Interacting Protein CYFIP1 in Prader-Willi and Fragile X Syndromes
![Role of FMRP Interacting Protein CYFIP1 in Prader-Willi and Fragile X Syndromes Yong-Hui Jiang, PhD, at Baylor College of Medicine, FRAXA research grant](https://www.fraxa.org/wp-content/uploads/2006/07/jiang-yong-hui-210x300.jpg)
With a $105,000 grant from FRAXA Research Foundation from 2005-2006, Dr. Yong-Hui Jiang at Baylor College of Medicine explored the relationship between Fragile X syndrome and Prader-Willi syndrome.
Read more